Last reviewed · How we verify

Detrol LA

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · FDA-approved active Small molecule

Detrol LA is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary muscle contractions and urinary urgency.

Detrol LA is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary muscle contractions and urinary urgency. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.

At a glance

Generic nameDetrol LA
SponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug classMuscarinic receptor antagonist
TargetM2 and M3 muscarinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaUrology
PhaseFDA-approved

Mechanism of action

Detrol LA (tolterodine tartrate extended-release) selectively antagonizes M2 and M3 muscarinic receptors in the detrusor muscle of the bladder. By blocking acetylcholine-mediated contractions, it decreases the frequency and urgency of urination and increases bladder capacity, providing symptomatic relief of overactive bladder.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results